Who owns Enliven Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ELVN from SEC Form 13F filings across 217 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 217 institutions disclosed 82.6M shares of Enliven Therapeutics, Inc. worth $3.79B — about 105.9% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
217
13F holders
$3.79B
value, 2026 filers
105.9%
of shares outstanding (82.6M sh)
36
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ELVN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 10.8M | $496.3M | 0.0% | 13.9% | +8.0% |
| 2 | ORBIMED ADVISORS LLC | 6.8M | $310.6M | 5.6% | 8.7% | 0.0% |
| 3 | Polar Capital Holdings Plc | 6.4M | $294.5M | 0.7% | 8.2% | -0.1% |
| 4 | BlackRock, Inc. | 5.7M | $261.8M | 0.0% | 7.3% | +31.0% |
| 5 | Commodore Capital LP | 3.3M | $150.1M | 11.6% | 4.2% | 0.0% |
| 6 | Vestal Point Capital, LP | 3.2M | $147.8M | 3.8% | 4.1% | -19.4% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $132.6M | 0.0% | 3.7% | +12.6% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.4M | $107.7M | 0.0% | 3% | -19.1% |
| 9 | Fairmount Funds Management LLC | 1.9M | $85.1M | 5.3% | 2.4% | 0.0% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $78.4M | 0.0% | 2.2% | +21.4% |
| 11 | STATE STREET CORP | 1.5M | $70.8M | 0.0% | 2% | +27.5% |
| 12 | Siren, L.L.C. | 1.5M | $67.6M | 1.6% | 1.9% | -16.9% |
| 13 | Bellevue Group AG | 1.5M | $67.3M | 1.4% | 1.9% | -1.4% |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.5M | $67.2M | 0.1% | 1.9% | +35.3% |
| 15 | Pictet Asset Management Holding SA | 1.3M | $60.8M | 0.1% | 1.7% | +14.1% |
| 16 | CITADEL ADVISORS LLC | 1.2M | $57.0M | 0.0% | 1.6% | -39.8% |
| 17 | MARSHALL WACE, LLP | 1.2M | $53.0M | 0.0% | 1.5% | +117.1% |
| 18 | Assenagon Asset Management S.A. | 1.2M | $52.9M | 0.1% | 1.5% | +276.4% |
| 19 | Logos Global Management LP | 1.1M | $49.5M | 2.7% | 1.4% | +132.3% |
| 20 | First Light Asset Management, LLC | 1.0M | $46.7M | 2.8% | 1.3% | -25.2% |
| 21 | NOVO HOLDINGS A/S | 1.0M | $45.8M | 3.1% | 1.3% | 0.0% |
| 22 | First Turn Management, LLC | 958,700 | $43.9M | 5.8% | 1.2% | +0.5% |
| 23 | SAMLYN CAPITAL, LLC | 936,167 | $42.9M | 0.7% | 1.2% | +2.6% |
| 24 | BAKER BROS. ADVISORS LP | 905,191 | $41.5M | 0.2% | 1.2% | 0.0% |
| 25 | Candriam S.C.A. | 846,451 | $38.9M | 0.2% | 1.1% | -6.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.